Forging a Lifeline: DoD Backs Revolutionary Tech to Combat War's Deadliest Foes!

A prestigious $2 million Department of Defense grant has been awarded to AREVA Institute to pioneer research with SeaStar Medical’s SCD therapy.
This groundbreaking study aims to tackle severe burns, inhalation injuries, and sepsis in warfighters by neutralizing deadly hyperinflammation.
The collaboration signifies a monumental step in saving lives on and off the battlefield, with potential to revolutionize critical care.

In a move poised to redefine battlefield medicine, the AREVA Institute and SeaStar Medical (Nasdaq: ICU) have announced a pivotal Department of Defense (DoD) grant, igniting a new front in the war against trauma's deadliest consequences^{2, 5}. Awarded through the highly competitive 2024 Military Burn Research Program (MBRP)—one of just four selected from 160 fierce contenders—this $2 million, three-year initiative will unleash SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy against the ravages of severe burns, inhalation injury, and sepsis in service members^{5, 7}.

The research, commencing July 2025, targets the silent killer: hyperinflammation. When a warfighter suffers catastrophic injuries, their own immune system can turn against them, unleashing a "cytokine storm" that causes organ failure and death. The SCD therapy offers a beacon of hope, a revolutionary device designed to selectively neutralize these over-active immune cells and halt the destructive cascade³. Integrated with existing CRRT systems, it aims to not just save lives but to promote organ recovery and potentially eliminate the need for long-term dialysis^{2, 5}.

"In my 25-year research career, this particular award and collaboration with SeaStar Medical has the potential to be one of the most impactful," declared Dr. Andriy Batchinsky, Principal Investigator at AREVA. His words echo the immense promise held by this venture—a promise to transform survival rates for combat casualties and civilian patients alike.

The AREVA Institute, one of the few global labs capable of such intensive, around-the-clock research, will spearhead this effort with administrative support from The Geneva Foundation^{1, 5}. Dr. Kevin Chung, SeaStar Medical’s CMO, lauded the award as a "major vote of confidence," underscoring the SCD therapy's potential to "optimize functional recovery" for the critically wounded⁵. This isn't just research; it's a lifeline in development, a testament to innovation aimed at the heart of military and civilian critical care.

Forging a Lifeline: DoD Backs Revolutionary Tech to Combat War's Deadliest Foes!

References

Stay Updated!